Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Matthew J. Kling, Varun Kesherwani, Nitish K. Mishra, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 10

Showing 10 citing articles:

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets
Haihong Qian, Min Zhu, Xinyu Tan, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Devendra Kumar, Ranjana Kanchan, Nagendra K. Chaturvedi
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Histone Phosphorylation in DNA Damage Response
Ping Gong, Zhaohui Guo, Shengping Wang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2405-2405
Open Access
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
Jérémy Ariey-Bonnet, Raphaël Bergès, Marie-Pierre Montero, et al.
EBioMedicine (2023) Vol. 95, pp. 104752-104752
Open Access | Times Cited: 8
The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies
Hasan Slika, Paolo Alimonti, Divyaansh Raj, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3889-3889
Open Access | Times Cited: 5
Targeting BRD4 with PROTAC degrader ameliorates LPS-induced acute lung injury by inhibiting M1 alveolar macrophage polarization
Difei Li, Yao Deng, Guanxi Wen, et al.
International Immunopharmacology (2024) Vol. 132, pp. 111991-111991
Closed Access | Times Cited: 1
Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer
Zhiyuan Yao, Peng Song, Wenjie Jiao
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
The current status and future trends of BET research in oncology
Siying Yu, Linna Long, Xiaorui Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 17, pp. e36888-e36888
Open Access
Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
Ting-Chao Chou
Elsevier eBooks (2024), pp. 181-218
Closed Access
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer
Lukas M. Bollmann, Friedrich Lange, Alexandra Hamacher, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3374-3374
Open Access
Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
Jérémy Ariey-Bonnet, Raphaël Bergès, Marie-Pierre Montero, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top